CTOs on the Move

NanoCellect Biomedical

www.nanocellect.com

 
NanoCellect`s mission is to facilitate biomedical breakthroughs by making cell analysis and sorting technology more affordable and easier to use. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF`s technology before launching the WOLF (our first product) in 2016. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts and recently backed by FusionX Ventures and other private investors.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

NanoCellect Biomedical raised $10M on 11/29/2017

Similar Companies

Aduro Biotech

Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.

Neoleukin

Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. We are creating next generation immunotherapies using breakthrough de novo protein design technology. We use natural protein complexes as inspiration to develop custom designed proteins with superior pharmaceutical properties.

Zero Gravity Solutions

Zero Gravity Solutions is an agricultural biotechnology public company commercializing its technology derived from and designed for Space with significant applications on Earth. These technologies are focused on providing valuable solutions to challenges facing world agriculture. ZGSI’s two primary categories of technologies aimed at sustainable agriculture are: 1) BAM-FX™ technology, a cost effective, ionic micronutrient delivery system for plants currently being introduced commercially into world agriculture by Zero Gravity’s wholly owned subsidiary BAM Agricultural Solutions and 2) Directed Selection™, utilized in the development and production, in the prolonged zero/micro gravity environment of the International Space Station, of large volumes of non-GMO, novel, patentable stem cells with unique and beneficial characteristics.

J Morrison Group

J Morrison Group is a Fullerton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.